scholarly journals Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Blood ◽  
2014 ◽  
Vol 124 (16) ◽  
pp. 2507-2513 ◽  
Author(s):  
Ayalew Tefferi ◽  
Paola Guglielmelli ◽  
Dirk R. Larson ◽  
Christy Finke ◽  
Emnet A. Wassie ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Essential Thrombocythemia ◽  
Blast Transformation ◽  
Term Survival ◽  
Free Survival ◽  
Long Term Survival ◽  
Mutational Status ◽  
Key Points

Key Points Survival in ET is superior to that of PV, regardless of mutational status, but remains inferior to the sex- and age-matched US population. JAK2/CALR/MPL mutational status is prognostically informative in PMF, regarding overall and leukemia-free survival.

scholarly journals Impact of postoperative complications on long-term survival of hepatocellular carcinoma patients after liver resection

2021 ◽  
Author(s):  
Susumu Mochizuki ◽  
Hisashi Nakayama ◽  
Yutaka Midorikawa ◽  
Tokio Higaki ◽  
Masamichi Moriguchi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Liver Resection ◽  
Pleural Effusion ◽  
Postoperative Complications ◽  
Recurrence Free Survival ◽  
Term Survival ◽  
Free Survival ◽  
Long Term Survival

Objective The effect of postoperative complications including red blood transfusion (BT) on long-term survival for hepatocellular carcinoma (HCC) is unknown. The purpose of this study was to define the relationship between postoperative complications and long-term survival in patients with HCC. Methods Postoperative complications of 1251 patients who underwent curative liver resection for HCC were classified, and their recurrence-free survival (RFS) and cumulative overall survival (OS) were investigated. Results Any complications occurred in 503 patients (40%). Five-year RFS and 5-year OS in the complication group were 21% and 56%, respectively, significantly lower than the respective values of 32% ( p < 0.001) and 68% ( p < 0.001) in the no-complication group (n=748). Complications related to RFS were postoperative BT [Hazard ratio (HR): 1.726, 95% confidence interval (CI): 1.338–2.228, p < 0.001], pleural effusion [HR: 1.434, 95% CI: 1.200–1.713, p < 0.001] using Cox-proportional hazard model. Complications related to OS were postoperative BT [HR: 1.843, 95%CI: 1.380-2.462, p < 0.001], ascites [HR: 1.562, 95% CI: 1.066–2.290 p = 0.022], and pleural effusion [HR: 1.421, 95% CI: 1.150–1.755, p = 0.001). Conclusions Postoperative complications were factors associated with poor long-term survival. Postoperative BT and pleural effusion, were noticeable complications that were prognostic factors for both recurrence-free survival and overall survival.

scholarly journals SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery

Blood ◽  
2018 ◽  
Vol 132 (17) ◽  
pp. 1737-1749 ◽  
Author(s):  
Elie Haddad ◽  
Brent R. Logan ◽  
Linda M. Griffith ◽  
Rebecca H. Buckley ◽  
Roberta E. Parrott ◽  
...  
Keyword(s):  
Immune Reconstitution ◽  
Cd4 Count ◽  
Immune Recovery ◽  
Term Survival ◽  
Long Term Survival ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Key Points ◽  
Cd4 Cell

Key Points The genetic cause of SCID impacts on survival and immune reconstitution and should be considered in tailoring HCT for individual patients. Total and naive CD4+ cell counts in SCID patients 6 and 12 months post-HCT predict long-term survival and sustained immune reconstitution.

scholarly journals BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

2019 ◽  
Vol 3 (22) ◽  
pp. 3740-3749 ◽  
Author(s):  
Tsila Zuckerman ◽  
Ron Ram ◽  
Luiza Akria ◽  
Maya Koren-Michowitz ◽  
Ron Hoffman ◽  
...  
Keyword(s):  
Older Adults ◽  
Acute Leukemia ◽  
Phase 1 ◽  
Intensive Therapy ◽  
High Dose ◽  
Term Survival ◽  
Long Term Survival ◽  
Key Points ◽  
High Dose Cytarabine

Key Points The majority of older adults or unfit acute leukemia patients are not offered intensive therapy, resulting in dismal long-term survival. A novel cytarabine prodrug BST-236 enables delivery of high-dose cytarabine and appears to be safe and efficacious in these patients.

scholarly journals Correlates of Long-Term Survival of Patients with pN+ Esophageal Squamous Cell Carcinoma after Esophagectomy

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Ming He ◽  
Zhan Qi ◽  
Rong Qiu ◽  
Yuanping Hu ◽  
Juan Li ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Survival Data ◽  
Term Survival ◽  
Free Survival ◽  
Long Term Survival

Esophageal squamous cell carcinoma (ESCC) is the most common pathological type of esophageal cancer in China. Patients with ESCC have poor long-term survival, especially those with lymphatic metastasis (pN + ESCC). In this retrospective study, we evaluated the correlates of long-term survival time of patients with pN + ESCC. A total of 453 patients with pN + ESCC who underwent surgical R0 resection between Jan 2008 and Sep 2011 were enrolled. The follow-up ended on December 2019. The clinical, pathological, inflammation-related factors and general survival data of these patients were analyzed using SPSS 22.0 software. The 1-, 3-, and 5-year overall survival (OS) rates were 73.7%, 34.6%, and 25.6%, respectively; the 1-, 3-, and 5-year disease-free survival (DFS) rates were 45.0%, 26.3%, and 20.4%, respectively. The median OS and DFS were 23 and 14 months, respectively. On multivariate analyses, gender, site of lesion, number of dissected lymph nodes, stage pTNM, adjuvant therapy, and neutrophil lymphocyte ratio were independent predictors of OS. Site of lesion, stage pTNM, and adjuvant therapy were independent predictors of DFS. Recursive partitioning analysis (RPA) scores of each patient were calculated based on the independent predictors of OS, and the patients were divided into 3 classes: low-risk, medium-risk, and high-risk. The OS, DFS, and local recurrence-free survival were significantly different among these three RPA classes P < 0.001 . Several factors showed an independent association with long-term postoperative survival of pN + ESCC patients after radical surgery. RPA scores can potentially be used to predict the prognosis of ESCC.

scholarly journals Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Blood ◽  
2015 ◽  
Vol 126 (24) ◽  
pp. 2578-2584 ◽  
Author(s):  
Gerhard Zugmaier ◽  
Nicola Gökbuget ◽  
Matthias Klinger ◽  
Andreas Viardot ◽  
Matthias Stelljes ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Kinetics ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Term Survival ◽  
Long Term Survival ◽  
Disease Response ◽  
Key Points ◽  
Minimal Residual

Key Points Ten of 36 patients (28%) achieved an OS ≥30 months in a blinatumomab study in relapsed/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response.

scholarly journals Calreticulin mutations and long-term survival in essential thrombocythemia

Leukemia ◽  
2014 ◽  
Vol 28 (12) ◽  
pp. 2300-2303 ◽  
Author(s):  
A Tefferi ◽  
E A Wassie ◽  
T L Lasho ◽  
C Finke ◽  
A A Belachew ◽  
...  
Keyword(s):  
Essential Thrombocythemia ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-term and quality of survival in patients treated for acute lymphoblastic leukemia during the pediatric age

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Lara Devilli ◽  
Chiara Garonzi ◽  
Rita Balter ◽  
Elisa Bonetti ◽  
Matteo Chinello ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Current Treatment ◽  
Event Free Survival ◽  
Term Survival ◽  
Free Survival ◽  
Long Term Survival

Long-term survival for acute lymphoblastic leukemia (ALL) in children improved over the last three decades up to 80-90% of affected patients. Consequently, the quality of life of survivors has become increasingly important. This study analyses the clinical features and outcome of 119 children with ALL, focusing on the quality of long-term survival in a subset of 22 patients over 18 years of age. Among this group, the 10-year event-free survival and overall survival were 83.1% (C.I. 74.0-89.2) and 88.4% (C.I. 80.9-93.1), respectively. Treatment related long-term medical complications were reported only in 2 patients (9.1%). Secondary school was completed successfully in 20 of 22 patients (89.9%). The remaining 2 patients were still attending at the time of the analysis. In conclusion, current treatment for ALL is well tolerated and does not compromise significantly the quality of life of survivors.

Sign in / Sign up

Export Citation Format

Share Document